October 11, 2020
Background on Company Novel scientific insights to unlock the full potential of B cell therapeutics Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020 Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation...
Read More